BOSTON--(BUSINESS WIRE)--PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that it has been named to the FlexJobs Top 100 Companies to Watch for Telecommuting and Remote Jobs in 2017 list for the fourth consecutive year. The list recognizes companies that are telecommuting-friendly, allowing for candidates to telecommute on a full- or part-time basis.
PAREXEL offers approximately 20 percent of its nearly 20,000 global employees flexible work options, including telecommuting, flexible schedules, and home-based employment. In North America, approximately 40 percent of PAREXEL’s employees take advantage of the Company’s telecommuting and flexible work opportunities. These employees represent a diverse cross section of positions, including clinical research, biostatistics, and regulatory affairs.
“We are pleased to be recognized as a leader in providing telecommuting and remote job opportunities,” said Tom McGoldrick, Corporate Vice President of Talent Acquisition, PAREXEL. “By offering remote and flexible work options, PAREXEL has developed a highly engaged, skilled, and satisfied workforce that allows us to continue delivering for our clients and helping them bring new treatments to patients in need.”
“More people are now professionally engaged in the knowledge economy, which naturally supports jobs that can be done from home. And as more companies embrace remote work in meaningful ways, more people will have greater access to broader career and employment opportunities, creating a positive ripple effect on our economy,” said Sara Sutton Fell, founder and CEO of FlexJobs.
About the Ranking
FlexJobs, a job service specializing in remote and flexible job opportunities, analyzed its database of more than 47,000 companies’ job posting history in 2016 to determine which companies posted the most remote-friendly job opportunities throughout the last year. To be considered, companies had to be telecommuting-friendly, either allowing for candidates to telecommute entirely or part of the time. In 2017, PAREXEL was included in the top third of the list.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 85 locations in 51 countries around the world, and had approximately 19,625 employees in the second quarter. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.